Avotaciclib clinical trials
Also written BEY1107.
How each study uses avotaciclib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the avotaciclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BEY1107
- 3
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
BeyondBio Inc. (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test avotaciclib.
- Nov 2026A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)Phase 1 · BeyondBio Inc.
- Nov 2026Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic CancerPhase 1/2 · BeyondBio Inc.
- Nov 2026A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal CancerPhase 1/2 · BeyondBio Inc.
Studies
Open first, then newest update. How each study uses avotaciclib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)RecruitingPhase 1BeyondBio Inc.NCT05769660Written as BEY1107How we know
- Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic CancerRecruitingPhase 1/2BeyondBio Inc.NCT03579836Written as BEY1107How we know
- A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal CancerRecruitingPhase 1/2BeyondBio Inc.NCT05093907Written as BEY1107How we know
Codes
What other systems call avotaciclib · ClinicalTrials.gg INT018656
- UNII (FDA) Z6BYC0F36EAVOTACICLIBOne source FDA
- NCI Thesaurus C163985AvotaciclibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z6BYC0F36E | AVOTACICLIB | One source FDA |
| NCI Thesaurus | C163985 | Avotaciclib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.